日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies

维奈托克治疗相关非核心结合因子急性髓系白血病的疗效

Senapati, Jayastu; Croden, Jennifer; Garcia-Manero, Guillermo; Takahashi, Koichi; Daver, Naval G; Kadia, Tapan M; Borthakur, Gautam; Short, Nicholas James; Jabbour, Elias; Haddad, Fadi; Marvin-Peek, Jennifer; Abbas, Hussein A; Bose, Prithviraj; Tang, Guilin; Loghavi, Sanam; Shpall, Elizabeth J; Ramdial, Jeremy; Popat, Uday R; Champlin, Richard E; Ravandi, Farhad; Kantarjian, Hagop M; Dinardo, Courtney D

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation

急性髓系白血病中的神经炎症变化:血脑屏障破坏和神经胶质细胞活化的证据

Gerds, Aaron T; Bose, Prithviraj; Hobbs, Gabriela S; Kuykendall, Andrew T; Neilson, Lynn M; Song, Jinlin; Klencke, Barbara; Harrison, Claire N; Febo, Marta; Sorcini, Daniele; Mirarchi, Alessandra; Cogliati, Paolo; Stella, Arianna; Sportoletti, Paolo; Ermakova, Olga; Mandarano, Martina; Marchetti, Maria Cristina; Riccardi, Carlo; Falini, Brunangelo; Migliorati, Graziella; Arcuri, Cataldo; Bruscoli, Stefano; Bereshchenko, Oxana

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

在骨髓纤维化复杂情况下选择JAK抑制剂:综述

Vachhani, Pankit; Mesa, Ruben; Mascarenhas, John; Rampal, Raajit; Oh, Stephen T; Vannucchi, Alessandro Maria; Fox, Maria Laura; Palandri, Francesca; Passamonti, Francesco; Kiladjian, Jean-Jacques; Azimi, Mahshid; Harrison, Claire; Bose, Prithviraj

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome

POT1肿瘤易感综合征的临床、遗传和家族特征

DiNardo, Courtney D; Croden, Jennifer; Abdel-Salam, Hiam M; Kadia, Tapan; Molica, Matteo; Bazinet, Alexandre; Bose, Prithviraj; Maiti, Abhishek; Haddad, Fadi; Burger, Jan; Kantarjian, Hagop; Wierda, William; Jain, Nitin; Ferrajoli, Alessandra

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机3期试验

Rampal, Raajit K; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T; Vannucchi, Alessandro M; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen T; Kuykendall, Andrew T; Patriarca, Andrea; Álvarez-Larrán, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Scandura, Joseph M; Lavie, David; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Boxhammer, Rainer; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire N; Mascarenhas, John

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

CDK7抑制剂联合疗法对转化为AML的骨髓增生性肿瘤的临床前疗效

Fiskus Warren, Mill Christopher P, Bose Prithviraj, Masarova Lucia, Pemmaraju Naveen, Dunbar Andrew, Birdwell Christine E, Davis John A, Das Kaberi, Hou Hanxi, Manshouri Taghi, Jain Antrix, Malovannaya Anna, Philip Kevin, Alhamadani Noor, Matthews Alicia, Lin Katie, Flores Lauren B, Loghavi Sanam, DiNardo Courtney, Su Xiaoping, Rampal Raajit K, Bhalla Kapil N

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis

欧洲白血病网关于骨髓纤维化新药安全性和有效性评价的标准

Marchetti, Monia; Vannucchi, Alessandro Maria; Mascarenhas, John O; Alvarez-Larran, Alberto; Bose, Prithviraj; Gale, Robert Peter; Harrison, Claire; Hehlmann, Rűdiger; Kiladjian, Jean-Jacques; Koschmieder, Steffen; Mesa, Ruben; Passamonti, Francesco; Rambaldi, Alessandro; Tefferi, Ayalew; Barbui, Tiziano

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

一项针对既往未接受治疗的骨髓增生异常综合征患者的阿扎胞苷联合伊匹木单抗、纳武利尤单抗或伊匹木单抗联合纳武利尤单抗的II期临床试验

Bouligny, Ian M; Montalban-Bravo, Guillermo; Sasaki, Koji; Daver, Naval; Jabbour, Elias; Alvarado, Yesid; DiNardo, Courtney D; Ravandi, Farhad; Borthakur, Gautam; Bose, Prithviraj; Pemmaraju, Naveen; Kornblau, Steven; Kadia, Tapan; Masarova, Lucia; Takahashi, Koichi; Andreeff, Michael; Bazinet, Alexandre; Yang, Hui; Kanagal-Shamanna, Rashmi; Hosing, Chitra; Pierce, Sherry; Meyer, Meghan; Huang, Xuelin; Garcia-Manero, Guillermo

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

tasquinimod联合疗法治疗晚期骨髓增生性肿瘤急变期患者的临床前疗效

Fiskus, Warren; Masarova, Lucia; Mill, Christopher P; Birdwell, Christine E; Das, Kaberi; Hou, Hanxi; Davis, John A; Jain, Antrix; Malovannaya, Anna; Manshouri, Taghi; Dunbar, Andrew; Sharma, Surbhi; Kadia, Tapan M; DiNardo, Courtney D; Bose, Prithviraj; Pemmaraju, Naveen; Loghavi, Sanam; Su, Xiaoping; Rampal, Raajit K; Törngren, Marie; Bhalla, Kapil N

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia

全反式维甲酸、三氧化二砷和吉妥珠单抗奥佐米星治疗急性早幼粒细胞白血病的II期研究的长期随访

Jen, Wei-Ying; Marvin-Peek, Jennifer; Kantarjian, Hagop M; Alvarado, Yesid; Borthakur, Gautam; Jabbour, Elias; Wierda, William; Kadia, Tapan M; Daver, Naval G; DiNardo, Courtney D; Short, Nicholas J; Jain, Nitin; Ferrajoli, Alessandra; Kornblau, Steven; Yilmaz, Musa; Ohanian, Maro; McCue, David; Burger, Jan; Hammond, Danielle; Patel, Keyur; Issa, Ghayas C; Pemmaraju, Naveen; Sasaki, Koji; Maiti, Abhishek; Abbas, Hussein A; Chien, Kelly; Takahashi, Koichi; Haddad, Fadi; Bose, Prithviraj; Masarova, Lucia; Montalban-Bravo, Guillermo; Swaminathan, Mahesh; Brandt, Mark; Pierce, Sherry; Garcia-Manero, Guillermo; Ravandi, Farhad